There are 360 resources available
46P - Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors
Presenter: David Oh
Session: Poster Display
161P - A Phase 1b Study to Evaluate IK-007 in Combination with Pembrolizumab (pembro) in Patients with Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Presenter: Anthony Tolcher
Session: Poster Display
47P - Phase 1 Study to Assess the Safety and Efficacy of P-BCMA-ALLO1, a Fully Allogeneic CAR-T Therapy, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Presenter: Mehmet Kocoglu
Session: Poster Display
48P - Phase II trial on vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in resected Glioblastoma (COMBI-GVAX): clinical results of the first step.
Presenter: Laura Ridolfi
Session: Poster Display
163P - Neoadjuvant Chemoradiotherapy plus Tislelizumab Followed by Surgery for Esophageal Carcinoma: An Interim Analysis of the Prospective, Single-arm, Phase II Trial
Presenter: Jinsong Yang
Session: Poster Display
49P - Exploiting multi-omic integrated data from DC-vaccinated melanoma patients for the generation of an advanced adoptive T cell therapy
Presenter: Jenny Bulgarelli
Session: Poster Display
164P - TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): a single-arm, multicenter phase II trial
Presenter: Junsheng Wang
Session: Poster Display
50P - Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer
Presenter: Dafne Quixabeira
Session: Poster Display